Researchers found that variations in four genes controlling inflammation are associated with insulin resistance in Mexican Americans. These findings may enable physicians to identify patients at high risk for developing diabetes and design therapies targeting these genes.
Researchers found that taking pioglitazone for three years significantly reduced the risk of developing type 2 diabetes in women who had previously had gestational diabetes. This is promising news for preventing and treating type 2 diabetes, as it may help stabilize beta-cell function.
A cross-sectional study of 2,162 men found that 38.7% had low testosterone levels and 23% had a history of diabetes. Men with diabetes and low T were 2.09 times more likely to have hypogonadism, a condition characterized by low testosterone production.
A study found that ACTOS reduced inflammation markers CRP and IL-6, improving glycemic control in patients with stable blood sugar levels. Treatment with ACTOS resulted in significant decreases in these markers compared to placebo.
A study of 580 women found that nearly half experienced persistent lymphedema, a condition causing fluid buildup in arms and hands. Lymphedema affects quality of life, requiring lifestyle changes such as compression garments.
Researchers used genetic engineering techniques to develop mice with overexpressed PKC-beta 2, demonstrating its role in the progression of diabetic kidney disease. The study found that albumin levels were tenfold higher and oxidative stress three times higher in these mice compared to normal mice.
A new study demonstrated add-on effects of ACTOS on diabetic dyslipidemia, reducing triglycerides and increasing HDL cholesterol. Patients with type 2 diabetes who switched from Avandia to ACTOS showed significant improvements in lipid levels, regardless of age or gender.
Research linking obesity and asthma suggests that weight loss can reduce eotaxin levels, a key inflammatory mediator. The study found that obese patients experienced significant reductions in eotaxin levels after losing weight, offering new hope for treating debilitating asthma symptoms.